Document is current

Article History

Received: 9 November 2024

Accepted: 9 December 2024

First Online: 7 February 2025

Declarations

:

: Yoshiaki Nakamura reports honoraria from Chugai Pharmaceutical and research funding from Genomedia, Guardant Health Japan, Tempus Labs, Roche Diagnostics, Daiichi Sankyo, PRA Health Sciences, and Chugai Pharmaceutical. Hideaki Bando reports honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, and Eli Lilly Japan and research funding from Ono Pharmaceutical. Eiji Oki reports honoraria from Bristol-Myers Squibb, Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Takeda Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, and Bayer Yakuhin and research funding from Guardant Health Japan. Hidehito Horinouchi reports honoraria from AstraZeneca, Chugai Pharmaceutical, and AbbVie and research funding from AbbVie, AstraZeneca, Chugai Pharmaceutical, and Bristol Myers Squibb. Yukinori Ozaki reports honoraria from Pfizer, Kyowa Kirin, Daiichi Sankyo, Eli Lilly Japan, and Chugai Pharmaceutical. Hiroji Iwata reports honoraria from AstraZeneca and Daiichi Sankyo and research funding from AstraZeneca, Daiichi Sankyo, Pfizer, and Chugai Pharmaceutical. Akihiro Ohba reports honoraria from Ono Pharmaceutical and research funding from Ono Pharmaceutical, Novartis Pharma, and Chugai Pharmaceutical. Taigo Kato reports honoraria from MSD. Hideaki Miyake reports honoraria from Janssen Pharmaceutical, Takeda Pharmaceutical, MSD, Eisai, Astellas, Sanofi, Pfizer, Sysmex, Ono Pharmaceutical, Astellas, and AstraZeneca; research funding from Ono Pharmaceutical, MSD, and Pfizer; and scholarship donations from PDRadiopharma, Takeda Pharmaceutical, and FUJIFILM. Masafumi Ikeda reports honoraria from Taiho Pharmaceutical, Novartis Pharma, Chugai Pharmaceutical, Nihon Servier, MSD, AstraZeneca, Teijin Pharma, Incyte Biosciences Japan, Eisai, and Takeda Pharmaceutical and research funding from MSD, Eisai, Chiome Bioscience, Syneos Health Clinical, Novartis Pharma, Eli Lilly Japan, Chugai Pharmaceutical, Bristol-Myers Squibb, Nihon Servier, Merus N.V., INVITAE, Delta-Fly Pharma, AstraZeneca, J-Pharma, Merck Biopharma, and Chiome Bioscience. Tatsuyuki Chiyoda reports research funding from Takeda Pharmaceutical and JSR. Kosei Hasegawa reports honoraria from Sanofi, MSD, Takeda Pharmaceutical, Chugai Pharmaceutical, and AstraZeneca and research funding from MSD and Takeda Pharmaceutical. Kenjiro Namikawa reports honoraria from Novartis Pharma. Takayuki Yoshino reports honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical, Merck Biopharma, Bayer Yakuhin, Ono Pharmaceutical, MSD K.K, and Sumitomo Corp.; research funding from Amgen, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, FALCO biosystems, Genomedia, Medical & Biological Laboratories, Merus N.V., Molecular Health GmbH, MSD, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer Japan, Roche Diagnostics, Sanofi, Sysmex, Taiho Pharmaceutical, and Takeda Pharmaceutical. Kiyoshi Hasegawa reports honoraria from Eisai and Chugai Pharmaceutical, research funding from Mochida Pharmaceutical and FUJIFILM Healthcare Laboratory, and scholarship donations from Taiho Pharmaceutical. The other authors declare no conflicts of interest.